Table of Contents
People on kidney dialysis face a constant, elevated risk of heart attacks, strokes, and sudden cardiac death.
Despite careful medical management, options to prevent these emergencies have remained limited, leaving clinicians with few tools that reliably reduce cardiovascular risk.
A large new clinical trial now suggests that a simple daily supplement may help close that gap.
Researchers report that high-dose fish oil substantially lowered the risk of major heart-related events in people receiving long-term dialysis – an effect far larger than typically seen in past supplement studies.
The work was led by Dr. Charmaine Lok at the University Health Network (UHN) in Toronto, whose research focuses on improving survival and heart health in patients with kidney failure.
That focus matters because dialysis patients often take many medications, yet few directly address the cardiovascular risks that ultimately claim so many lives.
Testing fish oil in dialysis
Researchers at UHN tested daily fish oil capsules in a randomized trial involving 1,228 adults receiving ongoing kidney dialysis.
Clinicians assigned each participant to fish oil or corn oil at random, and both patients and staff remained unaware of the assignments.
Sites at 26 centers across Canada and Australia followed participants for several years, recording every major cardiac or stroke-related crisis.
The main outcome combined cardiac death, heart attack, stroke, and limb loss from severe arterial disease into a single measure.
A striking reduction in risk
Over 3.5 years, people taking fish oil experienced far fewer serious heart-related emergencies than those given corn oil.
In practical terms, heart attacks, strokes, and related events occurred about half as often in the fish oil group during the study period.
Deaths from any cause were also less common, and strokes showed the largest reduction among all measured outcomes.
These results point to meaningful protection, even though dialysis patients still live with serious health risks tied to kidney failure.
How omega-3s affect the heart
Omega-3 fats in fish oil can change how cells handle fats and chemical signaling, which may help calm blood vessels under stress.
At higher doses, these fats can reduce inflammation and may make blood less likely to form dangerous clots.
Evidence summarized in a scientific advisory shows that omega-3 supplements have delivered inconsistent heart benefits across large population trials.
Dialysis patients may differ because kidney failure alters blood chemistry and heart rhythm, meaning these mechanisms need closer tracking.
Fish oil dose and quality matter
Federal guidance explains that many fish oil capsules contain modest amounts of omega-3s, and labeled doses can vary widely.
In the trial, participants took about 0.14 ounces of omega-3 fats daily, far above what many store-bought bottles deliver.
“I don’t know that you would have the same effect if you just bought something over the counter,” said Dr. Lok.
Safety in a fragile group
High-dose fish oil raises understandable concerns about bleeding, stomach upset, and interactions with the many drugs used in dialysis care.
In this study, adherence remained similar between groups, and researchers saw no meaningful difference in overall adverse events.
That finding matters because dialysis patients often take blood thinners, and even small changes in clotting can become serious quickly.
Safety still depends on dose and product purity, so clinics will need clear protocols before recommending fish oil more broadly.
Which patients benefit most
The benefit matters most for people on maintenance hemodialysis, in which blood is cleaned by a machine several times a week, because their event risk remains high.
The protective effect appeared whether participants entered the trial with or without a prior history of cardiovascular events.
Because the trial focused on in-center dialysis, it cannot answer whether people using home dialysis would see similar protection.
The results also do not apply to earlier stages of kidney disease, where inflammation and heart risk follow a different timeline.
Implications for dialysis care
Dialysis units could integrate fish oil into routine care more easily than many therapies that require frequent laboratory adjustments.
Clinicians would need to choose a consistent formulation, match the studied dose, and coordinate with pharmacies that serve dialysis centers.
Because many patients manage limited budgets, an over-the-counter product might look appealing, yet quality control can be uneven.
Clinics may also face questions about oversight, since the Food and Drug Administration regulates supplements under rules that differ from those governing drug approval.
Future research directions
The size of the reported reduction demands careful replication, especially given that many past supplement studies have shown far smaller effects.
Future trials should measure blood omega-3 levels, track changes in heart rhythm, and test whether benefits persist with different formulations.
Researchers also need to identify which dialysis patients benefit most, since care spans wide differences in age, coexisting illnesses, and clinic routines.
Taken together, the trial results, plausible biological mechanisms, and the practical fit of supplementation in dialysis units suggest fish oil could help fill a rare prevention gap.
Until stronger confirmation arrives, it makes sense to view fish oil as a promising tool rather than a free-for-all. Careful decision-making, product quality, and validation in new settings remain essential before it becomes routine care.
The study is published in the New England Journal of Medicine.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
—–
